Glycan Columns


More than two thirds of recombinant biopharmaceutical products on the market are glycoproteins, and nearly every stage of their manufacture is carefully monitored and regulated to ensure consistency in quality, safety, and effectiveness. Consequently, international regulatory agencies require use of state-of-the-art glycan analyses methods to help ensure the successful development and commercialization of effective and safe glycosylated biotherapeutics. To address this need, Waters offers a variety of robust, reproducible, complementary, information-rich analytical methods for this application.

HILIC for Large Biomolecules It is now possible to use HILIC to glean previously unattainable information from intact proteins (with or without glycosylation), protein fragments, and complex, released glycans.
HILIC for Released Glycans ACQUITY UPLC and XBridge Glycan BEH Amide 130 Å Columns are best suited for the analysis of released, N-labeled glycans using pre-column labeling with 2-AB, 2-AA, or Waters innovative and enabling RapiFluor-MS reagent.
Mixed-Mode für freigesetzte Glykane Die Glycan BEH C18 AX Säulen sind mit einer Reversed Phase-/Anionenaustausch-Phase gepackt, die saure Glykane über Ladung und hydrophobe Wechselwirkungen trennt. Sie bietet so eine orthogonale Selektivität zu den HILIC Amid-Säulen.
Sialic Acid and Monosaccharide Analyses UPLC, UHPLC, and HPLC-based C18 columns that assist scientists with the analysis and quantitation of important glycan derived components.